Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$49.01M-20.1%-$50.22M-26.6%-$40.67M-19.2%-$36.12M-14.7%-$40.8M-43.0%
$537K+4.7%$525K-9.0%$500K0.0%$500K0.0%$513K+8.5%
$8.72M-3.8%$9.88M+27.6%$8.09M+17.5%$7.73M+48.0%$9.06M+86.0%
-$42.54M-12.4%-$38.59M-43.2%-$34.78M-27.0%-$32.58M-24.8%-$37.87M-32.4%
$260K+491%$73K-73.4%$105K-79.8%$34K-84.6%$44K-85.2%
$2.43M-94.5%-$162.17M$43.9M+116%
$12.17M+448%$3.98M+37.3%$1.66M-50.2%$188.23M+9,543%$2.22M-99.1%
-$27.94M-438%$15.15M+582%$2.6M$8.26M+115%
-$42.8M-12.9%-$38.67M-42.0%-$34.88M-25.0%-$32.62M-23.9%-$37.91M-31.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Edgewise Therapeutics, Inc. generate?
Edgewise Therapeutics, Inc. (EWTX) generated -$148.5M in operating cash flow over the trailing twelve months.
What is Edgewise Therapeutics, Inc.'s free cash flow?
After $472.0K of capital expenditures, Edgewise Therapeutics, Inc.'s free cash flow was -$149.0M over the trailing twelve months, down 24.8% year over year.
Where does Edgewise Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.